Why Pfizer Inc. (PFE) stock moved
No significant move on Nov 18, 2026 (−1.4%, close-to-close). Latest notable session: Nov 5, 2026.
Why Pfizer Inc. (PFE) fell 3.0% on November 5, 2026
Pfizer Inc. (PFE) fell 3.0% on November 5, 2026, closing at $29.88 versus $30.79 the prior session (close-to-close, from daily closes). After reporting Q3 earnings that beat consensus EPS by 18.37% ($0.87 vs. $0.73 estimate) on 2026-11-03. The company also raised 2026 revenue guidance to $62–64 billion and reported 32% growth in launched/acquired products. Source: FMP price data; BestStocks detection.
Pfizer Inc. (PFE) moved -3.89% from $31.09 to $29.88 on 2026-11-05, two days after reporting Q3 earnings that beat consensus EPS by 18.37% ($0.87 vs. $0.73 estimate) on 2026-11-03. The company also raised 2026 revenue guidance to $62–64 billion and reported 32% growth in launched/acquired products.
What to watch next: Pfizer's next scheduled earnings are 2027-02-02 (consensus EPS estimate: $0.72).
Earlier sessions that moved PFE
- +2.6%Following a strong Q3 2026 earnings beat and raised full-year guidance.
- +3.0%Preview of over 50 abstracts for IDWeek 2026 (Oct 21–24), featuring new infectious disease clinical data including pneumococcal and RSV programs, per BusinessWire.
Pfizer Inc. (PFE) shares fell 1.9% to $27.53 as of November 19, 2026, a modest decline from the prior close of $28.06. BestStocks flagged the session as a major change for PFE. The move is tied to company news. Below, we break down what changed for PFE, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
Company News
Pfizer secures $1.5 billion Blackstone co-funding for obesity drug berobenatide development through 2028. Risk-sharing deal reduces Pfizer's R&D burden while validating obesity program value; potential blockbuster market.
What it means for Pfizer Inc. investors
For Pfizer Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Positive price momentum; Positive price momentum. Weighing against that: Negative session, down 1.9%; New SEC filing — review for material disclosures. Because peers moved similarly, the shift looks more macro- or sector-driven than a change in PFE's fundamentals. Wall Street's consensus price target sits at $31.50, implying +14.4% upside from $27.53. BestStocks rates the overall signal quality low (45/100). With earnings roughly 75 days out, the next report is the most likely near-term test of the move.
PFE price reaction
PFE last traded at $27.53, down $0.54 (-1.91%) from the previous close of $28.06. The session traded on 0.7× average volume (below avg), so participation was unremarkable. Its healthcare peer group moved a median -2.5% over the same stretch, leaving PFE ahead of the group by 0.6 points. Over the past month the stock has ranged between $27.53 and $30.79, and it currently sits about 0% of the way up that band.
Bullish and bearish analyst opinions on Pfizer Inc. (PFE)
The consensus analyst price target on Pfizer Inc. (PFE) is $31.50, 14.4% above the recent $27.53. Over the past 90 days analysts logged 0 upgrades, 10 maintains, and 0 downgrades. Here is how the bullish and bearish cases on PFE line up.
The bullish case
- Wall Street's consensus price target of $31.50 implies +14.4% upside from $27.53.
- The Street's most bullish target is $40.00 (+45.3%).
- Positive price momentum.
The bearish case
- The most bearish analyst target is $27.00 (-1.9%).
- Negative session, down 1.9%.
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Nov 19, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for PFE
Frequently asked questions about PFE
Why did Pfizer Inc. (PFE) stock move?
Pfizer Inc. (PFE) fell 3.0% on November 5, 2026, closing at $29.88 versus $30.79 the prior session (close-to-close, from daily closes). After reporting Q3 earnings that beat consensus EPS by 18.37% ($0.87 vs. $0.73 estimate) on 2026-11-03. The company also raised 2026 revenue guidance to $62–64 billion and reported 32% growth in launched/acquired products. Source: FMP price data; BestStocks detection.
How much did PFE stock fall?
PFE lost 1.91% ($0.54) versus the prior close of $28.06, last trading at $27.53 on 0.7× average volume.
When is Pfizer Inc.'s next earnings date?
PFE's next earnings report is estimated for 2027-02-02 — about 75 days away.
What is the analyst price target for PFE?
The consensus analyst price target for PFE is $31.50, about 14.4% above the current $27.53. Over the past 90 days, analysts recorded 0 upgrades, 10 maintains, and 0 downgrades.
Is the PFE move company-specific or sector-wide?
BestStocks classifies it as a sector-wide move: the peer group moved a median -2.5% against PFE's -1.9%. PFE ranks top 3 of 7 peers.
How BestStocks tracks PFE
This page is generated automatically by BestStocks' change-detection system after company news was detected and verified against independent data sources. It draws on 20 tracked change events for PFE, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 19, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
